DaehanPharmaceutical

대한약품 · 023910

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$114.6M (₩158.1B)

Overview

DaehanPharmaceutical makes intravenous fluids and ampoule-based medicines, the basic liquid drugs that hospitals and clinics use to hydrate and nourish patients who cannot take medication by mouth.

It supplies these products primarily to hospitals and clinics, while also reaching pharmacy consumers through over-the-counter items such as lens-cleaning solutions and sodium chloride wash. Listed on KOSDAQ, Korea's small-cap and technology board, the company derives the large majority of its revenue from the hospital and clinic channel, giving it a concentrated but stable customer base.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$151.2M
▲ +2.2% YoY
Operating profit · FY2025
US$22.6M
▼ −18.1% YoY
Net income · FY2025
US$20M
▼ −18.1% YoY

Revenue

  • FY2023US$142M
  • FY2024US$148M
  • FY2025US$151.2M

Operating profit

  • FY2023US$25.9M
  • FY2024US$27.6M
  • FY2025US$22.6M

Net income

  • FY2023US$20.6M
  • FY2024US$24.5M
  • FY2025US$20M

Key ratios (FY2025)

ROE
9.2%
Debt/Eq
15.8%
Op. margin
14.9%
Net margin
13.3%
Rev. YoY
▲ +2.2%

Why it matters

Korean pharmaceutical pricing, distribution, and advertising are subject to direct government regulation, which shapes the competitive and margin environment for all domestic drug suppliers.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.